HomeNDC LookupDrug shortages › Doxycycline Hyclate Tablet, Delayed Release

Doxycycline Hyclate Tablet, Delayed Release shortage

Doxycycline Hyclate Tablet, Delayed Release is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Sep 22, 2026.

To Be Discontinued ⚠ Supply risk: High Anti-Infective 2 products 54 days First posted Jul 30, 2026 Updated Jul 30, 2026
Here’s the bottom line

Teva is permanently stopping its doxycycline hyclate delayed-release tablets (50 mg and 200 mg), and no supply from Teva remains. Other makers still list doxycycline hyclate delayed-release tablets at 75 mg, plus regular doxycycline hyclate tablets at 100 mg.

Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
2
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/2
Affected strengths supplied
54
Days in shortage
100
Medicaid Rx (2025)
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 22, 2026 · today

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Doxycycline Hyclate Tablet, Delayed Release. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
2 NDCs
To be discontinued 2
Affected strengths still supplied
Among manufacturers reporting this shortage
0/2 strengths
No supply 2
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Doxycycline Hyclate Tablet, Delayed Release from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Hikma Pharmaceuticals USA Inc. Actavis Pharma, Inc. Major Pharmaceuticals Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS Ajanta Pharma USA Inc. Cranbury Pharmaceuticals, LLC Acella Pharmaceuticals, LLC
Plus 11 alternative dosage forms of Doxycycline Hyclate Tablet, Delayed Release.
See all other options & details →
Shortage timeline
  1. Jul 30, 2026
    Currently in shortage
    2 of 2 products affected.
  2. Jul 30, 2026
    First reported to the FDA
    2 products first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 2 NDCS click to expand
Status NDC / product Strength Availability Related information Reason
To Be Discontinued Doxycycline Hyclate, Tablet, Delayed Release, 200 mg (NDC 0591-4575-60) NDC 00591-4575-60 Discontinuation of the manufacture of the drug
To Be Discontinued Doxycycline Hyclate, Tablet, Delayed Release, 50 mg (NDC 0591-4550-22) NDC 00591-4550-22 Discontinuation of the manufacture of the drug

These rows are manufacturer reports to the FDA for Doxycycline Hyclate Tablet, Delayed Release — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Doxycycline Hyclate Tablet, Delayed Release? options further down this page.

Why is Doxycycline Hyclate Tablet, Delayed Release in shortage?

Teva Pharmaceuticals has decided to permanently stop making two specific versions of delayed-release doxycycline hyclate tablets: the 50 mg tablets (NDC 0591-4550-22) and the 200 mg tablets (NDC 0591-4575-60). This is a permanent decision, not a temporary shortage — they are fully discontinuing production of both of these products. Teva did not share a specific public reason for why they made this business decision.

It's worth knowing that this report reflects only what Teva has filed with the FDA about their products. Other manufacturers of delayed-release doxycycline hyclate are covered separately, so this does not necessarily mean the medication is going away from the market entirely.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Doxycycline Hyclate Tablet, Delayed Release, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Doxycycline Hyclate Tablet, Delayed Release?

Doxycycline hyclate delayed-release tablets are currently on the FDA shortage list. I want to walk you through what this means and the practical steps you can take.

Both strengths on this record — the 50 mg and the 200 mg delayed-release tablets — have no available source reported right now. The reason listed for both is that the manufacturer (Teva) is discontinuing production. Because this is a discontinuation rather than a temporary supply gap, this particular product may not return, so a conversation with your prescriber is the right next step.

It's worth knowing that this report reflects only the manufacturer who filed it. The same medicine, doxycycline hyclate delayed-release, is still on the market from another maker (Heritage/Avet) in several strengths, including a 200 mg delayed-release tablet. Your pharmacy may be able to source one of these, though it may not be in local stock.

Here is what I suggest:

  • Do not stop or change your dose on your own — keep taking it as prescribed while you sort this out.
  • Ask your pharmacy to check wholesalers and other manufacturers for the same medicine.
  • Ask your prescriber or pharmacist about a clinician-chosen option or a strength that matches your dose.

Manufacturer contact numbers are listed on this page for reference; your pharmacy usually handles those calls.

This is general, national information and may not match your local pharmacy's stock.

See “Where else can I get Doxycycline Hyclate Tablet, Delayed Release?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Doxycycline guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Doxycycline guide →

Where else can I get Doxycycline Hyclate Tablet, Delayed Release?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Doxycycline Hyclate Tablet, Delayed Release is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Doxycycline Hyclate DOXYCYCLINE HYCLATE 100 mg/1 Tablet, Coated · Oral Hikma Pharmaceuticals USA Inc. 00143-2112-05
Doxycycline Hyclate DOXYCYCLINE HYCLATE 100 mg/1 Tablet Actavis Pharma, Inc. 00591-5553-00
Doxycycline Hyclate DOXYCYCLINE HYCLATE 100 mg/1 Tablet, Coated · Oral Major Pharmaceuticals 00904-0430-04
Doxycycline Hyclate Delayed Release DOXYCYCLINE HYCLATE 75 mg/1 Tablet, Delayed Release · Oral Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 23155-0141-01
Doxycycline Hyclate Delayed Release DOXYCYCLINE HYCLATE 100 mg/1 Tablet, Delayed Release · Oral Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 23155-0142-01
Doxycycline Hyclate Delayed Release DOXYCYCLINE HYCLATE 150 mg/1 Tablet, Delayed Release · Oral Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 23155-0143-01
Doxycycline Hyclate Delayed Release DOXYCYCLINE HYCLATE 200 mg/1 Tablet, Delayed Release · Oral Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 23155-0611-04
Doxycycline Hyclate DOXYCYCLINE HYCLATE 100 mg/1 Tablet, Film Coated · Oral PURACAP LABORATORIES LLC DBA BLU PHARMACEUTICALS 24658-0310-01
Doxycycline Hyclate DOXYCYCLINE HYCLATE 75 mg/1 Tablet · Oral Ajanta Pharma USA Inc. 27241-0153-02
Doxycycline Hyclate DOXYCYCLINE HYCLATE 150 mg/1 Tablet · Oral Ajanta Pharma USA Inc. 27241-0154-02
Doxycycline Hyclate DOXYCYCLINE HYCLATE 100 mg/1 Tablet · Oral Cranbury Pharmaceuticals, LLC 27808-0234-01
Doxycycline DOXYCYCLINE HYCLATE 100 mg/1 Tablet, Coated · Oral Acella Pharmaceuticals, LLC 42192-0501-05

Alternative dosage forms of Doxycycline Hyclate Tablet, Delayed Release

A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:

Therapeutic equivalents & pricing 8 productsclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Doxycycline Hyclate 50 mgNDC 00591-4550-22 Actavis 120 tablets $1.569 AB Availability likely
Doxycycline Hyclate 50 mgNDC 43547-0462-12 Solco 120 tablets $1.569 AB Availability likely
Doxycycline Hyclate 200 mgNDC 00591-4575-60 Actavis 60 tablets $3.701 AB Availability likely
Doxycycline Hyclate 200 mgNDC 43547-0325-06 Solco 60 tablets $3.701 AB Availability likely
Doxycycline Hyclate 200 mgNDC 68308-0716-30 Mayne 30 tablets $3.701 Availability likely
Doxycycline Hyclate Delayed Release 200 mgNDC 23155-0611-04 Heritage 250 tablets AB FDA listed
Doxycycline Hyclate 200 mgNDC 46708-0484-31 Alembic 100 tablets AB FDA listed
Doxycycline Hyclate 200 mgNDC 62332-0484-30 Alembic 30 tablets AB FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Doxycycline Hyclate Tablet, Delayed Release — that fall in the same broad treatment class (tetracycline antibiotics) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 070917
GCN 34586
HICL code 004013
Ingredient (HICL) Doxycycline Hyclate
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W1
Therapeutic class — intermediate (HIC2) Antibiotics
HIC3 code W1C
Therapeutic class — specific (HIC3) Tetracycline Antibiotics
AHFS code 08:12.24.00
AHFS class Tetracycline Antibiotics
FDB label name DOXYCYCLINE HYC DR 200 MG TAB
FDB brand name Doxycycline Hyclate
Legend status F — Federal legend — prescription drug or device
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other anti-infective shortages

Doxycycline Hyclate Tablet, Delayed Release shortage FAQs

Is Doxycycline Hyclate Tablet, Delayed Release in shortage?
Yes — the FDA currently lists Doxycycline Hyclate Tablet, Delayed Release in shortage (status: “To Be Discontinued”, first reported Jul 30, 2026). 2 of 2 products are affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Doxycycline Hyclate, Tablet, Delayed Release, 200 mg (NDC 0591-4575-60) (NDC 00591-4575-60); Doxycycline Hyclate, Tablet, Delayed Release, 50 mg (NDC 0591-4550-22) (NDC 00591-4550-22). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Doxycycline Hyclate Tablet, Delayed Release be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Doxycycline Hyclate Tablet, Delayed Release somewhere?
Other manufacturers (Hikma Pharmaceuticals USA Inc., Actavis Pharma, Inc., Major Pharmaceuticals and others) still market it and have not reported a shortage. 11 alternative dosage forms of Doxycycline Hyclate Tablet, Delayed Release are also listed. See “Where else can I get Doxycycline Hyclate Tablet, Delayed Release?” above — stock still varies by pharmacy.
What should I do if I take Doxycycline Hyclate Tablet, Delayed Release?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Doxycycline Hyclate Tablet, Delayed Release shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages